Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Science Advances · 2023
DOI: 10.1126/sciadv.ade8778 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2023. Verfasst von Seyed Arad Moghadasi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Vaccines and drugs have helped reduce disease severity and blunt the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, ongoing virus transmission, continuous evolution, and increasing selective pressures have the potential to yield viral variants capable of resisting these interventions. Here, we investigate the susceptibility of natural variants of the main protease [M pro ; 3C-like protease (3CL pro )] of SARS-CoV-2 to protease inhibitors. Multiple single amino acid changes in M pro confer resistance to nirmatrelvir (the active component of Paxlovid). An additional clinical-stage inhibitor, ensitrelvir (Xocova), shows a different resistance mutation profile. Importantly, phylogenetic analyses indicate that several of these resistant variants have pre-existed the introduction of these drugs into the human population and are capable of spreading. These results encourage the monitoring of resistance variants and the development of additional protease inhibitors and other antiviral drugs with different mechanisms of action and resistance profiles for combinatorial therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA.
- Institute of Virology, Medical University of Innsbruck, Innsbruck, Austria.
- Texas Biomedical Research Institute, San Antonio, TX 78227, USA.
- Department of Zoonotic Diseases, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt.
- Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.
- Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA.
ORCID-Profile: Seyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, Christina Nnabuife, Fiona L Kearns, Chengjin Ye, Sofia N Moraes, Francesco Costacurta, Morgan A Esler, Hideki Aihara, Dorothee von Laer, Luis Martinez-Sobrido, Timothy Palzkill, Rommie E Amaro, Reuben S Harris
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
Zitieren
APA
Moghadasi, S. A., Heilmann, E., Khalil, A. M., Nnabuife, C., Kearns, F. L., Ye, C., Moraes, S. N., Costacurta, F., Esler, M. A., Aihara, H., von Laer, D., Martinez-Sobrido, L., Palzkill, T., Amaro, R. E., & Harris, R. S. (2023). Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Science Advances. https://doi.org/10.1126/sciadv.ade8778
Vancouver
Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. Science Advances. 2023. doi:10.1126/sciadv.ade8778
BibTeX
@article{Moghadasi2023,
author = {Moghadasi, Seyed Arad and Heilmann, Emmanuel and Khalil, Ahmed Magdy and Nnabuife, Christina and Kearns, Fiona L and Ye, Chengjin and Moraes, Sofia N and Costacurta, Francesco and Esler, Morgan A and Aihara, Hideki and von Laer, Dorothee and Martinez-Sobrido, Luis and Palzkill, Timothy and Amaro, Rommie E and Harris, Reuben S},
title = {Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors},
journal = {Science Advances},
year = {2023},
doi = {10.1126/sciadv.ade8778}
}
EUVIMED